ARTICLE | Company News

WuXi Biologics, TaiMed rise after FDA approves mAb for HIV

March 7, 2018 6:35 PM UTC

WuXi Biologics Inc. (HKSE:2269) climbed HK$3.15 to HK$61.90 on Wednesday after FDA approved Trogarzo ibalizumab-uiyk, a mAb the company manufactures, to treat certain patients with HIV-1 infection. WuXi Biologics said the therapy is the first biologic drug manufactured in China that FDA has approved (see BioCentury Extra, March 6).

WuXi Biologics' partner TaiMed Biologics Inc. (TPEx:4147), which submitted Trogarzo's NDA to FDA, rose NT$21 (10%) to NT$234 on Wednesday. Theratechnologies Inc. (TSX:TH), which has U.S. rights to market and distribute the drug under a deal with TaiMed fell C$0.03 to C$9.20 on Wednesday after gaining 28% on Tuesday. FDA announced the approval during Toronto market hours Tuesday, and prior to Asian trading hours Wednesday...